Tenant startup AxoSim has been awarded a two year NIH Small Business Technology Transfer (STTR) grant for $1,770,000 to advance their nerve-on-a-chip technology for predictive preclinical drug testing. AxoSim is developing clinically relevant models of human neurological tissue to bring much needed therapies to market faster and more efficiently. In partnership with Tulane, this project will further validate the company’s proprietary peripheral nerve model for screening drugs against neurotoxicity. Peripheral neuropathy manifests itself in up to 40% of patients receiving chemotherapy and is the number one reason patients stop receiving treatment. The startup will also develop machine learning algorithms to improve the model’s predictive power over time. AxoSim has grown to 11 team members since launching in 2014 and beginning to receive Commercialization consulting assistance.
September 21, 2017 — Read more at New Orleans CityBusiness